# A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

> **NCT00537511** · PHASE1,PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 22 (actual)

## Conditions studied

- Carcinoma, Small Cell

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Cisplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT00537511
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02-01
- **Primary completion:** 2010-11-01
- **Final completion:** 2010-12-01
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** This study was terminated for administrative reasons.
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00537511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00537511, "A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00537511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*